arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Bioventus Inc.

BVS
$14.12 ▲ +0.14 (+1.04%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
7 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
57
Health
Fair
Bearish
auto_awesome

Analytical Summary

Bioventus Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $940.7M
Dividend Yield
Revenue Growth -0.9%
Op. Margin 9.5%
ROIC 12.4%
FCF / Share $1.08
Trailing P/E 41.5x
Price / Book 5.1x
FCF Yield 7.7%
Debt / Equity 1.52
info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$568.09M
↓ -0.9%
Net Income Profit after all expenses
$22.73M
↑ +162.9%
Operating Margin Operating profit as % of sales
9.5%
↑ +458.5% 55th
FCF / Share Free cash flow per share
$1.08
↑ +84.9%
Long-Term Debt Long-term obligations
$278.95M
↓ -9.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
56
Returns
75
Financial Health
17
Cash Quality
92

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 25 quarters